November 16 event, featuring KOL perspectives on emerging HBV therapies
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat liver and , a company with unmet medical needs in viral diseases, announced today that it will host a virtual KOL event with Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, to review its Phase 1 CAM-E drug candidate Latest results and next steps for ALG-000184 The treatment landscape for chronic hepatitis B (CHB), as well as the unmet needs and current treatment landscape for patients with CHB, on November 16, 2023 at 1:30 PM ET. To register, click here.
Phase 1 data will be presented at the latest poster session at the Liver Conference® American Association of Liver Diseases Meeting on November 13, 2023 (Poster #5028-C).
The formal presentation will be followed by a live Q&A.
about Mark Surkovsky, MD
Mark Sulkowski, MD, is a professor of medicine at the Johns Hopkins University School of Medicine and chief of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as medical director of the Division of Infectious Diseases and the Viral Hepatitis Center in the Division of Gastroenterology/Hepatology in the Department of Medicine, as well as senior associate dean for clinical trials. He received his MD degree from Temple University School of Medicine, Philadelphia, PA (1992), trained in internal medicine at Duke University School of Medicine, Durham, NC (1995), and completed his fellowship in infectious diseases at Johns Hopkins University Medical Specialist Training (1998) University School of Medicine.
Professor Sulkowski is the principal investigator of more than 120 clinical trials related to the management of viral hepatitis B and C in HIV-coinfected and non-HIV-coinfected individuals. He is a global principal investigator on more than a dozen trials, including the largest clinical trial of a treatment for hepatitis C (New England Journal of Medicine, 2009) and a pioneering study of combination therapy with HCV NS5A and a direct HCV inhibitor. NS5B nonstructural protein (New England Journal of Medicine, 2014). He is the former chair of the NIH-funded Adult AIDS Clinical Trials Group (ACTG) Hepatitis Translational Science Group, where he led translational research in liver diseases, namely hepatitis B and hepatitis C viruses. He was elected to membership in the American Society for Clinical Investigation (2011) and the American College of Physicians (2017).
Professor Sulkowski is a member of numerous professional societies, including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). He has published more than 300 peer-reviewed articles and his work has appeared widely in Annals of Internal Medicine, New England Journal of Medicine, Journal of the American Medical Association, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology “Study”. In 2017, 2018 and 2019, he was named a Highly Cited Researchers (Clarivate Analytics), defined as being among the top 1% of researchers globally based on the number of citations to their papers in 21 fields of science and social sciences.
About Arrigos
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with a mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to leverage its team’s deep expertise and decades of drug development experience in liver and viral diseases to discover and develop drugs targeting non-alcoholic steatohepatitis (NASH) and viruses with high unmet medical need, such as potential best treatments for coronaviruses and chronic viruses). Hepatitis B (CHB).
forward-looking statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be deemed “forward-looking statements.” Forward-looking statements are often, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate” and other similar words. “Expectations” and other similar terms referring to future results. Such forward-looking statements are subject to significant risks and uncertainties that could cause our development plans, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including the clinical development of Aligos stages, the process of designing and conducting clinical trials, the regulatory approval process, the timing of regulatory filings, challenges related to the manufacturing of drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property rights, and other matters that may affect the adequacy of Aligos. capital resources to fund operations, reliance on third parties for manufacturing and development work, and the impact of global events and other macroeconomic conditions on Aligos’ business. There are risks and uncertainties related to the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements. For a further description of the nature of, and the overall risks associated with, Aligos’ business, please see Aligos’ quarterly report on Form 10-Q filed with the SEC on November 2, 2023 and future periodic reports that will be filed with the SEC. Reports. Except as required by law, Aligos assumes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Media Contact
Veronica Eames
Life Sciences Newsletter
Veames@lifescicomms.com
Investor Contact
Dr. Corey Davis
life sciences consultant
+1 212 915 2577
cdavis@lifesciadvisors.com
